These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18215605)

  • 1. Heart failure disease management programs: a cost-effectiveness analysis.
    Chan DC; Heidenreich PA; Weinstein MC; Fonarow GC
    Am Heart J; 2008 Feb; 155(2):332-8. PubMed ID: 18215605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cost-effectiveness of disease management in systolic heart failure.
    Miller G; Randolph S; Forkner E; Smith B; Galbreath AD
    Med Decis Making; 2009; 29(3):325-33. PubMed ID: 19147835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure.
    Galbreath AD; Krasuski RA; Smith B; Stajduhar KC; Kwan MD; Ellis R; Freeman GL
    Circulation; 2004 Dec; 110(23):3518-26. PubMed ID: 15531765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of telephonic disease management in heart failure.
    Smith B; Hughes-Cromwick PF; Forkner E; Galbreath AD
    Am J Manag Care; 2008 Feb; 14(2):106-15. PubMed ID: 18269306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
    Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
    Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure.
    Collins SP; Schauer DP; Gupta A; Brunner H; Storrow AB; Eckman MH
    Am J Emerg Med; 2009 Mar; 27(3):293-302. PubMed ID: 19328373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
    Soto Alvarez J; González Vilchez F
    An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease.
    Oba Y
    Am J Manag Care; 2009 Feb; 15(2):97-104. PubMed ID: 19284806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure.
    Postmus D; Pari AA; Jaarsma T; Luttik ML; van Veldhuisen DJ; Hillege HL; Buskens E
    Am Heart J; 2011 Dec; 162(6):1096-104. PubMed ID: 22137084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
    Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
    Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
    Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
    J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
    Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
    Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.
    Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH).
    Jaarsma T; van der Wal MH; Lesman-Leegte I; Luttik ML; Hogenhuis J; Veeger NJ; Sanderman R; Hoes AW; van Gilst WH; Lok DJ; Dunselman PH; Tijssen JG; Hillege HL; van Veldhuisen DJ;
    Arch Intern Med; 2008 Feb; 168(3):316-24. PubMed ID: 18268174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do patients with heart failure need a case manager?
    Annema C; Luttik ML; Jaarsma T
    J Cardiovasc Nurs; 2009; 24(2):127-31. PubMed ID: 19242278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
    Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
    Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.